Neurophysiological and neurochemical animal models of schizophrenia: Focus on glutamate

Behavioural Brain Research

Volumn 204, Issue 2, 2009, Pages 352-362

  Bickel, Stephan ^a   Javitt, Daniel C ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Animal models; Cognitive disorders; Event related potentials; Glutamate; Glycine; Negative symptoms; Neurophysiology; NMDA; PCP; Schizophrenia

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; AMPHETAMINE; DOPAMINE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ARTICLE; AUDITORY CORTEX; AUDITORY MEMORY; BRAIN ELECTROPHYSIOLOGY; CLINICAL TRIAL; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; HUMAN; MISMATCH NEGATIVITY; NEUROCHEMISTRY; NEUROPHYSIOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REFRACTORY PERIOD; SCHIZOPHRENIA;

ACOUSTIC STIMULATION; AMPHETAMINE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; GLUTAMIC ACID; HAPLORHINI; HUMANS; MICRODIALYSIS; N-METHYLASPARTATE; RATS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNAPTIC TRANSMISSION;

EID: 69249209812     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.05.005     Document Type: Article

References (144)

1. Abi-Dargham A., Kegeles L.S., Zea-Ponce Y., Mawlawi O., Martinez D., Mitropoulou V., et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55 (2004) 1001-1006
2. Abi-Saab W.M., D'Souza D.C., Moghaddam B., and Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31 Suppl. 2 (1998) 104-109
3. Alain C., Woods D.L., and Knight R.T. A distributed cortical network for auditory sensory memory in humans. Brain Res 812 (1998) 23-37
4. Astikainen P., Ruusuvirta T., Wikgren J., and Penttonen M. Memory-based detection of rare sound feature combinations in anesthetized rats. Neuroreport 17 (2006) 1561-1564
5. Aultman J.M., and Moghaddam B. Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berl) 153 (2001) 353-364
6. Balla A., Hashim A., Burch S., Javitt D.C., Lajtha A., and Sershen H. Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem Res 26 (2001) 1001-1006
7. Balla A., Koneru R., Smiley J., Sershen H., and Javitt D.C. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 25 (2001) 157-164
8. Balla A., Sershen H., Serra M., Koneru R., and Javitt D.C. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology 28 (2003) 34-44
9. Barth D.S., and Di S. Three-dimensional analysis of auditory-evoked potentials in rat neocortex. J Neurophysiol 64 (1990) 1527-1536
10. Bickel S., Lipp H.P., and Umbricht D. Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function. Neuropsychopharmacology (2007)
11. Bickel S., Lipp H.P., and Umbricht D. Impaired attentional modulation of auditory evoked potentials in N-methyl-d-aspartate NR1 hypomorphic mice. Genes Brain Behav 6 (2007) 558-568
12. Borgmann C., Ross B., Draganova R., and Pantev C. Human auditory middle latency responses: influence of stimulus type and intensity. Hear Res 158 (2001) 57-64
13. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94 (1997) 2569-2574
14. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29 (1998) 142-147
15. Budd T.W., Barry R.J., Gordon E., Rennie C., and Michie P.T. Decrement of the N1 auditory event-related potential with stimulus repetition: habituation vs. refractoriness. Int J Psychophysiol 31 (1998) 51-68
16. Butler P.D., and Javitt D.C. Early-stage visual processing deficits in schizophrenia. Curr Opin Psychiatry 18 (2005) 151-157
17. Butler P.D., Martinez A., Foxe J.J., Kim D., Zemon V., Silipo G., et al. Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain (2006)
18. Buzsaki G. Theta oscillations in the hippocampus. Neuron 33 (2002) 325-340
19. Cardenas V.A., McCallin K., Hopkins R., and Fein G. A comparison of the repetitive click and conditioning-testing P50 paradigms. Electroencephalogr Clin Neurophysiol 104 (1997) 157-164
20. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1 (1988) 179-186
21. Connolly P.M., Maxwell C., Liang Y., Kahn J.B., Kanes S.J., Abel T., et al. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Res 29 (2004) 1179-1188
22. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 3 (1996) 241-253
23. Csepe V., Karmos G., and Molnar M. Effects of signal probability on sensory evoked potentials in cats. Int J Neurosci 33 (1987) 61-71
24. Curran H.V., and Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction (Abingdon, England) 96 (2001) 749-760
25. Dafny N., and Rigor B.M. Dose effects of ketamine on photic and acoustic field potentials. Neuropharmacology 17 (1978) 851-862
26. de Bruin N.M., Ellenbroek B.A., Cools A.R., Coenen A.M., and van Luijtelaar E.L. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl) 142 (1999) 9-17
27. Di S., and Barth D.S. The functional anatomy of middle-latency auditory evoked potentials: thalamocortical connections. J Neurophysiol 68 (1992) 425-431
28. Ehlers C.L., Kaneko W.M., Wall T.L., and Chaplin R.I. Effects of dizocilpine (MK-801) and ethanol on the EEG and event-related potentials (ERPS) in rats. Neuropharmacology 31 (1992) 369-378
29. Ehlers C.L., and Somes C. Long latency event-related potentials in mice: effects of stimulus characteristics and strain. Brain Res 957 (2002) 117-128
30. Ehrlichman R.S., Maxwell C.R., Majumdar S., and Siegel S.J. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J Cogn Neurosci 20 (2008) 1403-1414
31. Erwin R.J., Mawhinney-Hee M., Gur R.C., and Gur R.E. Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry 30 (1991) 430-442
32. Erwin R.J., Shtasel D., and Gur R.E. Effects of medication history on midlatency auditory evoked responses in schizophrenia. Schizophr Res 11 (1994) 251-258
33. Fritz J.B., Elhilali M., David S.V., and Shamma S.A. Auditory attention-focusing the searchlight on sound. Curr Opin Neurobiol 17 (2007) 437-455
34. Gallinat J., Mulert C., Bajbouj M., Herrmann W.M., Schunter J., Senkowski D., et al. Frontal and temporal dysfunction of auditory stimulus processing in schizophrenia. Neuroimage 17 (2002) 110-127
35. Giard M.H., Perrin F., Pernier J., and Bouchet P. Brain generators implicated in the processing of auditory stimulus deviance: a topographic event-related potential study. Psychophysiology 27 (1990) 627-640
36. Godey B., Schwartz D., de Graaf J.B., Chauvel P., and Liegeois-Chauvel C. Neuromagnetic source localization of auditory evoked fields and intracerebral evoked potentials: a comparison of data in the same patients. Clin Neurophysiol 112 (2001) 1850-1859
37. Gonzalez-Burgos G., and Lewis D.A. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 34 (2008) 944-961
38. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
39. Heekeren K., Daumann J., Neukirch A., Stock C., Kawohl W., Norra C., et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) 199 (2008) 77-88
40. Homayoun H., and Moghaddam B. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex 16 (2006) 93-105
41. Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27 (2007) 11496-11500
42. Huotilainen M., Winkler I., Alho K., Escera C., Virtanen J., Ilmoniemi R.J., et al. Combined mapping of human auditory EEG and MEG responses. Electroencephalogr Clin Neurophysiol 108 (1998) 370-379
43. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9 (1987) 12-35
44. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
45. Javitt D.C., Schroeder C.E., Steinschneider M., Arezzo J.C., and Vaughan Jr. H.G. Demonstration of mismatch negativity in the monkey. Electroencephalogr Clin Neurophysiol 83 (1992) 87-90
46. Javitt D.C., Steinschneider M., Schroeder C.E., Vaughan Jr. H.G., and Arezzo J.C. Detection of stimulus deviance within primate primary auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res 667 (1994) 192-200
47. Javitt D.C., Steinschneider M., Schroeder C.E., and Arezzo J.C. Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci USA 93 (1996) 11962-11967
48. Javitt D.C., Jayachandra M., Lindsley R.W., Specht C.M., and Schroeder C.E. Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP). Clin Neurophysiol 111 (2000) 833-836
49. Javitt D.C., Shelley A.M., Silipo G., and Lieberman J.A. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch Gen Psychiatry 57 (2000) 1131-1137
50. Javitt D.C., Balla A., Burch S., Suckow R., Xie S., and Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29 (2004) 300-307
51. Javitt D.C., Hashim A., and Sershen H. Modulation of striatal dopamine release by glycine transport inhibitors. Neuropsychopharmacology 30 (2005) 649-656
52. Javitt D.C. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19 (2006) 151-157
53. Javitt D.C., Spencer K.M., Thaker G.K., Winterer G., and Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7 (2008) 68-83
54. Kamondi A., Acsady L., Wang X.J., and Buzsaki G. Theta oscillations in somata and dendrites of hippocampal pyramidal cells in vivo: activity-dependent phase-precession of action potentials. Hippocampus 8 (1998) 244-261
55. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
56. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48 (2000) 627-640
57. Kegeles L.S., Martinez D., Kochan L.D., Hwang D.R., Huang Y., Mawlawi O., et al. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43 (2002) 19-29
58. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., and Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 26 (2006) 1604-1615
59. Knight R.T., Hillyard S.A., Woods D.L., and Neville H.J. The effects of frontal and temporal-parietal lesions on the auditory evoked potential in man. Electroencephalogr Clin Neurophysiol 50 (1980) 112-124
60. Kraus N., McGee T., Littman T., Nicol T., and King C. Nonprimary auditory thalamic representation of acoustic change. J Neurophysiol 72 (1994) 1270-1277
61. Kreitschmann-Andermahr I., Rosburg T., Meier T., Volz H.P., Nowak H., and Sauer H. Impaired sensory processing in male patients with schizophrenia: a magnetoencephalographic study of auditory mismatch detection. Schizophr Res 35 (1999) 121-129
62. Kreitschmann-Andermahr I., Rosburg T., Demme U., Gaser E., Nowak H., and Sauer H. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res Cogn Brain Res 12 (2001) 109-116
63. Kujala T., Tervaniemi M., and Schroger E. The mismatch negativity in cognitive and clinical neuroscience: theoretical and methodological considerations. Biol Psychol 74 (2007) 1-19
64. Lakatos P., Shah A.S., Knuth K.H., Ulbert I., Karmos G., and Schroeder C.E. An oscillatory hierarchy controlling neuronal excitability and stimulus processing in the auditory cortex. J Neurophysiol 94 (2005) 1904-1911
65. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93 (1996) 9235-9240
66. Laruelle M., Iyer R.N., al-Tikriti M.S., Zea-Ponce Y., Malison R., Zoghbi S.S., et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25 (1997) 1-14
67. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42 (1998) 211-221
68. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., and Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46 (1999) 56-72
69. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20 (2000) 423-451
70. Laruelle M., Abi-Dargham A., van Dyck C., Gil R., D'Souza D.C., Krystal J., et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47 (2000) 371-379
71. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology (2007)
72. Lazar R., and Metherate R. Spectral interactions, but no mismatch negativity, in auditory cortex of anesthetized rat. Hear Res 181 (2003) 51-56
73. Lecourtier L., Homayoun H., Tamagnan G., and Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 62 (2007) 739-746
74. Lee J., and Park S. Working memory impairments in schizophrenia: a meta-analysis. J Abnorm Psychol 114 (2005) 599-611
75. Leung S., Croft R.J., O'Neill B.V., and Nathan P.J. Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls. Psychopharmacology (Berl) 196 (2008) 451-460
76. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., et al. Subunit-selective modulation of GABA type a receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry (2008)
77. Liegeois-Chauvel C., Musolino A., Badier J.M., Marquis P., and Chauvel P. Evoked potentials recorded from the auditory cortex in man: evaluation and topography of the middle latency components. Electroencephalogr Clin Neurophysiol 92 (1994) 204-214
78. Light G.A., and Braff D.L. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62 (2005) 127-136
79. Linn G.S., O'Keeffe R.T., Lifshitz K., Schroeder C., and Javitt D.C. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology 192 (2007) 27-38
80. Logothetis N.K. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos Trans R Soc Lond B: Biol Sci 357 (2002) 1003-1037
81. Lu Z.L., Williamson S.J., and Kaufman L. Human auditory primary and association cortex have differing lifetimes for activation traces. Brain Res 572 (1992) 236-241
82. Lu Z.L., Williamson S.J., and Kaufman L. Behavioral lifetime of human auditory sensory memory predicted by physiological measures. Science 258 (1992) 1668-1670
83. Lutkenhoner B., and Steinstrater O. High-precision neuromagnetic study of the functional organization of the human auditory cortex. Audiol Neurootol 3 (1998) 191-213
84. Makeig S., Westerfield M., Jung T.P., Enghoff S., Townsend J., Courchesne E., et al. Dynamic brain sources of visual evoked responses. Science 295 (2002) 690-694
85. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II. Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23 (2003) 285-300
86. Mathiak K., Rapp A., Kircher T.T., Grodd W., Hertrich I., Weiskopf N., et al. Mismatch responses to randomized gradient switching noise as reflected by fMRI and whole-head magnetoencephalography. Hum Brain Mapp 16 (2002) 190-195
87. Maxwell C.R., Liang Y., Weightman B.D., Kanes S.J., Abel T., Gur R.E., et al. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology 29 (2004) 739-746
88. Maxwell C.R., Ehrlichman R.S., Liang Y., Trief D., Kanes S.J., Karp J., et al. Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther 316 (2006) 315-324
89. McEvoy L., Levanen S., and Loveless N. Temporal characteristics of auditory sensory memory: neuromagnetic evidence. Psychophysiology 34 (1997) 308-316
90. Miller D.W., and Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40 (1996) 57-62
91. Mitzdorf U. Properties of the evoked potential generators: current source-density analysis of visually evoked potentials in the cat cortex. Int J Neurosci 33 (1987) 33-59
92. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17 (1997) 2921-2927
93. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281 (1998) 1349-1352
94. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
95. Molholm S., Martinez A., Ritter W., Javitt D.C., and Foxe J.J. The neural circuitry of pre-attentive auditory change-detection: an fMRI study of pitch and duration mismatch negativity generators. Cereb Cortex 15 (2005) 545-551
96. Naatanen R., and Picton T. The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. Psychophysiology 24 (1987) 375-425
97. Naatanen R. Attention and brain function (1992), Lawrence Erlbaum Associates, NJ
98. Naatanen R., Paavilainen P., Rinne T., and Alho K. The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol 118 (2007) 2544-2590
99. Naatanen R., and Kahkonen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol (2008) 1-11
100. Narendran R., Frankle W.G., Keefe R., Gil R., Martinez D., Slifstein M., et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162 (2005) 2352-2359
101. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., et al. The MATRICS consensus cognitive battery. Part 1. Test selection, reliability, and validity. Am J Psychiatry 165 (2008) 203-213
102. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33 (1999) 523-533
103. Oranje B., van Berckel B.N., Kemner C., van Ree J.M., Kahn R.S., and Verbaten M.N. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22 (2000) 293-302
104. Oranje B., Gispen-de Wied C.C., Verbaten M.N., and Kahn R.S. Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol. Biol Psychiatry 52 (2002) 887-895
105. Pantev C., Bertrand O., Eulitz C., Verkindt C., Hampson S., Schuierer G., et al. Specific tonotopic organizations of different areas of the human auditory cortex revealed by simultaneous magnetic and electric recordings. Electroencephalogr Clin Neurophysiol 94 (1995) 26-40
106. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13 (2007) 1102-1107
107. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 158 (2008) 226-247
108. Pekkonen E., Katila H., Ahveninen J., Karhu J., Huotilainen M., and Tiihonen J. Impaired temporal lobe processing of preattentive auditory discrimination in schizophrenia. Schizophr Bull 28 (2002) 467-474
109. Picton T.W., Alain C., Woods D.L., John M.S., Scherg M., Valdes-Sosa P., et al. Intracerebral sources of human auditory-evoked potentials. Audiol Neurootol 4 (1999) 64-79
110. Pincze Z., Lakatos P., Rajkai C., Ulbert I., and Karmos G. Separation of mismatch negativity and the N1 wave in the auditory cortex of the cat: a topographic study. Clin Neurophysiol 112 (2001) 778-784
111. Pincze Z., Lakatos P., Rajkai C., Ulbert I., and Karmos G. Effect of deviant probability and interstimulus/interdeviant interval on the auditory N1 and mismatch negativity in the cat auditory cortex. Brain Res 13 (2002) 249-253
112. Reite M., Teale P., Zimmerman J., Davis K., and Whalen J. Source location of a 50 ms latency auditory evoked field component. Electroencephalogr Clin Neurophysiol 70 (1988) 490-498
113. Rinne T., Alho K., Ilmoniemi R.J., Virtanen J., and Naatanen R. Separate time behaviors of the temporal and frontal mismatch negativity sources. Neuroimage 12 (2000) 14-19
114. Rosburg T., Boutros N.N., and Ford J.M. Reduced auditory evoked potential component N100 in schizophrenia-a critical review. Psychiatry Res (2008)
115. Ruusuvirta T., Penttonen M., and Korhonen T. Auditory cortical event-related potentials to pitch deviances in rats. Neurosci Lett 248 (1998) 45-48
116. Ruusuvirta T., Koivisto K., Wikgren J., and Astikainen P. Processing of melodic contours in urethane-anaesthetized rats. Eur J Neurosci 26 (2007) 701-703
117. Sambeth A., Maes J.H., van L.G., Molenkamp I.B., Jongsma M.L., and Van Rijn C.M. Auditory event-related potentials in humans and rats: effects of task manipulation. Psychophysiology 40 (2003) 60-68
118. Scherg M., and von C.D. Psychoacoustic and electrophysiologic correlates of central hearing disorders in man. Eur Arch Psychiatry Neurol Sci 236 (1986) 56-60
119. Schonwiesner M., Novitski N., Pakarinen S., Carlson S., Tervaniemi M., and Naatanen R. Heschl's gyrus, posterior superior temporal gyrus, and mid-ventrolateral prefrontal cortex have different roles in the detection of acoustic changes. J Neurophysiol 97 (2007) 2075-2082
120. Sershen H., Balla A., Aspromonte J.M., Xie S., Cooper T.B., and Javitt D.C. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: Implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function. Neurochem Int 52 (2008) 119-129
121. Shah A.S., Bressler S.L., Knuth K.H., Ding M., Mehta A.D., Ulbert I., et al. Neural dynamics and the fundamental mechanisms of event-related brain potentials. Cereb Cortex 14 (2004) 476-483
122. Shaw N.A. The auditory evoked potential in the rat-a review. Prog Neurobiol 31 (1988) 19-45
123. Shelley A.M., Ward P.B., Catts S.V., Michie P.T., Andrews S., and McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 30 (1991) 1059-1062
124. Shelley A.M., Silipo G., and Javitt D.C. Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr Res 37 (1999) 65-79
125. Siegel S.J., Connolly P., Liang Y., Lenox R.H., Gur R.E., Bilker W.B., et al. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28 (2003) 675-682
126. Slifstein M., Kolachana B., Simpson E.H., Tabares P., Cheng B., Duvall M., et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry 13 (2008) 821-827
127. Steinschneider M., Arezzo J., and Vaughan Jr. H.G. Phase-locked cortical responses to a human speech sound and low-frequency tones in the monkey. Brain Res 198 (1980) 75-84
128. Tamminga C.A., Holcomb H.H., Gao X., and Lahti A.C. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 10 Suppl. 3 (1995) 29-37
129. Thonnessen H., Zvyagintsev M., Harke K.C., Boers F., Dammers J., Norra C., et al. Optimized mismatch negativity paradigm reflects deficits in schizophrenia patients. A combined EEG and MEG study. Biol Psychol 77 (2008) 205-216
130. Tikhonravov D., Neuvonen T., Pertovaara A., Savioja K., Ruusuvirta T., Naatanen R., et al. Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Res 1203 (2008) 97-102
131. Turetsky B.I., Greenwood T.A., Olincy A., Radant A.D., Braff D.L., Cadenhead K.S., et al. Abnormal auditory n100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry 64 (2008) 1051-1059
132. Uhlhaas P.J., Haenschel C., Nikolic D., and Singer W. The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull 34 (2008) 927-943
133. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., and Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57 (2000) 1139-1147
134. Umbricht D., Koller R., Vollenweider F.X., and Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 51 (2002) 400-406
135. Umbricht D., Koller R., and Bieber K. Ketamine-induced deficits in encoding in healthy volunteers: comparison to corresponding deficits in schizophrenia. Schizophr Res 67 (2004) 21
136. Umbricht D., Vyssotky D., Latanov A., Nitsch R., Brambilla R., D'Adamo P., et al. Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res 1019 (2004) 189-200
137. Umbricht D., and Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76 (2005) 1-23
138. Umbricht D., Vyssotki D., Latanov A., Nitsch R., and Lipp H.P. Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice?. Clin Neurophysiol 116 (2005) 353-363
139. van Berckel B.N., Oranje B., van Ree J.M., Verbaten M.N., and Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl) 137 (1998) 271-281
140. van Berckel B.N., Kegeles L.S., Waterhouse R., Guo N., Hwang D.R., Huang Y., et al. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31 (2006) 967-977
141. Weinberger D.R. Genetic mechanisms of psychosis: in vivo and postmortem genomics. Clin Ther 27 Suppl. A (2005) S8-S15
142. Winkler I., Karmos G., and Naatanen R. Adaptive modeling of the unattended acoustic environment reflected in the mismatch negativity event-related potential. Brain Res 742 (1996) 239-252
143. Zouridakis G., and Boutros N.N. Stimulus parameter effects on the P50 evoked response. Biol Psychiatry 32 (1992) 839-841
144. Zouridakis G., Simos P.G., and Papanicolaou A.C. Multiple bilaterally asymmetric cortical sources account for the auditory N1m component. Brain Topogr 10 (1998) 183-189